Drugs / Cal-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03593187 | Jan 2019 → Jul 2020 | HIV infectious disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cal-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03593187 ↗ |
| Known as | LVsh5/C46 | “Cal-1 (LVsh5/C46) drug product” NCT03593187 ↗ |
| Modality | Cell therapy | “Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct” NCT03593187 ↗ |